Data suggest that intravitreal bevacizumab increases the risk of thromboembolism, and some studies have raised the possibility of a link between bevacizumab and myocardial infarction (MI), while other studies did not find such a relationship.
Anti-vascular endothelial growth factor (VEGF) therapy has become the main treatment for vascular leakage, and the anti-VEGF agent bevacizumab is frequently used off-label in intravitreal injections given its favorable cost effectiveness compared with other anti-VEGF therapies. However, some data suggest that intravitreal bevacizumab increases the risk of thromboembolism, and some studies have raised the possibility of a link between bevacizumab and myocardial infarction (MI), while other studies did not find such a relationship.
In a study published in Medicine, investigators reviewed medical records of all patients treated with intravitreal bevacizumab during 2016 at a single hospital in the Republic of Korea. Patients (n = 724) all received injections of 1.25 mg of bevacizumab and were grouped according to whether they were receiving bevacizumab injections for age-related macular degeneration (AMD), diabetes-related complications, or retinal vein occlusion (RVO). The researchers then investigated the prevalence of MI within 2 months of injection. In total, patients received 1870 injections.
At 2 months posttreatment, 7 patients were diagnosed with MI. Of the 274 patients with AMD, 2 (0.73%) were diagnosed; of the 311 patients with diabetes-related complications, 3 (0.96%) were diagnosed; and of the 139 patients with RVO, 2 (1.44%) were diagnosed. There was no significant difference in MI prevalence after injection according to the reason for receiving the injection (P = .785). The researchers say that they could not determine the significance of group differences in prevalence of MI given the small sample size, but the average number of injections was lowest in the patients with RVO, and the average age of the patients with RVO was lower than that of the patients with AMD.
This finding “…may indicate that there is no association between [bevacizumab] injection and the development of MI, not only because there was no significant difference but also because more MIs occurred in patients with DM and RVO, suggesting that the MI was caused by systemic vascular disorders and not by [bevacizumab] injections. However, it is also possible that DM- or RVO-induced damage to the blood-retinal barrier could have affected the systemic circulation and induced vascular damage,” say the authors. However, providers should exercise caution when administering intravitreal bevacizumab, especially to patients with risk factors for MI.
Reference
Kwon JW, Donghyun J, Yoon LT. The association between myocardial infarction and intravitreal bevacizumab injection. Medicine. 2018;97(13):0198. doi: 10.1097/MD.0000000000010198.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.